TranCYST PUBLICATIONS

 

2017
Malas TB
, Formica C, Leonhard WN, Rao P, Granchi Z, Roos M, Peters DJ, ‘t Hoen PAMeta-analysis of Polycystic Kidney Disease expression profiles defines strong involvement of injury repair processes. Am J Physiol Renal Physiol,  Feb 1 2017. [Epub ahead of print]

 

2016
Devuyst O
, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol Dec 5, 2016. [Epub ahead of print].

Lerner J, Bagattin A, Verdeguer F, Makinistoglu MP, Garbay S, Felix T, Heidet L, Pontoglio M. Human mutations affect the epigenetic/bookmarking function of HNF1B. Nucleic Acids Res 44: 8097-8111, 2016.

Mao Z, Chong J, Ong AC. Autosomal Dominant Polycystic Kidney: recent advances in clinical management. Nucleic Acids Res 44: 8097-8111, 2016.

Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Klein J, Jankowski V, Bae KT, Chapman AB, Kistler AD. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant 2016 Jul 5. [Epub ahead of print]

Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clin J Am Soc Nephrol 11: 785-794, 2016.

Terryn S, Tanaka K, Lengelé JP, Olinger E, Dubois-Laforgue D, Garbay S, Kozyraki R, Van Der Smissen P, Christensen EI, Courtoy PJ, Bellanné-Chantelot C, Timsit J, Pontoglio M, Devuyst O. Tubular proteinuria in patients with HNF1α mutations: HNF1α drives endocytosis in the proximal tubule. Kidney Int 89: 1075-1089, 2016.


PhD thesis
Fiorentino A
Title: Glomerulogenesis and renal tubular differentiation : Role of HNF1beta
Université Paris Descartes, Département Développement, Génétique, Reproduction, Neurobiologie et Vieillissement (DGRNV)
Date: 13 December 2016
Pages: 1-208.

Pejchinovski M
Title: The role of urinary peptide markers in diagnosis and prognosis of severe renal diseases
Klinik für Nephrologie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin
Date: 11 October 2016
Pages: 1-67.


2015
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88: 17-27, 2015.

Devuyst O, Luciani A. Chloride transporters and receptor-mediated endocytosis in the renal proximal tubule. J Physiol 593: 4151-4164, 2015.

Le Corre S, Viau A, Burtin M, El-Karoui K, Cnops Y, Terryn S, Debaix H, Bérissi S, Gubler MC, Devuyst O, Terzi F. Cystic gene dosage influences kidney lesions after nephron reduction. Nephron 129: 42-51, 2015.

Ong AC, Devuyst O, Knebelmann B, Walz G; ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385: 1993-2002, 2015. Erratum in Lancet 385: 2576, 2015.

Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney Int 88: 699-710, 2015.

Pejchinovski M, Hrnjez D, Ramirez-Torres A, Bitsika V, Mermelekas G, Vlahou A, Zürbig P, Mischak H, Metzger J, Koeck T. Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics. Proteomics Clin Appl 9: 453-468, 2015.

Pejchinovski M, Klein J, Ramírez-Torres A, Bitsika V, Mermelekas G, Vlahou A, Mullen W, Mischak H, Jankowski V. Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteomics Clin Appl 9: 531-542, 2015.

Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TDL, Pavik I, Ho TA, Serra AL, Rotar LUrinary Biomarkers at Early ADPKD Disease Stage. PLoS One 10: e0123555, 2015.


2014
Petzold K, Gansevoort RT, Ong ACRotar L, Eckardt KU, Köttgen A, Pirson Y, Remuzzi G, Sandford R, Tesar V, Ecder T, Chaveau D, Torra R, Budde K, Le Meur Y, Wüthrich RP,
Serra AL. Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrol Dial Transplant, 29: 26-32, 2014. (Erratum)

Rotar L, Serra AL, Petzold K. Tolvaptan zur Therapie der autosomal-dominanten polyzystischen Nierenerkrankung – aktueller Stand. Schweiz Med Forum 14: 350-351, 2014.